- Home
- CLDX
as 03-31-2025 4:00pm EST
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | HAMPTON |
| Market Cap: | 1.3B | IPO Year: | 2008 |
| Target Price: | $54.29 | AVG Volume (30 days): | 749.8K |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $17.63 - $47.00 | Next Earning Date: | 05-05-2025 |
| Revenue: | $7,020,000 | Revenue Growth: | 1.99% |
| Revenue Growth (this year): | -50.47% | Revenue Growth (next year): | 27.01% |
Latest Celldex Therapeutics Inc. News
CLDX Breaking Stock News: Dive into CLDX Ticker-Specific Updates for Smart Investing
Zacks
7 days ago
Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last?
MT Newswires
12 days ago
Morgan Stanley Initiates Celldex Therapeutics at Overweight With $46 Price Target
GlobeNewswire
a month ago
Celldex Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire
a month ago
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
GlobeNewswire
a month ago
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
Simply Wall St.
a month ago
Celldex Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line
Zacks
a month ago
Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates
Associated Press Finance
a month ago
Celldex: Q4 Earnings Snapshot
Compare CLDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CLDX Celldex Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.